论文部分内容阅读
目的制定系统性红斑狼疮(SLE)患者红细胞补体受体Ⅰ型(CR1)天然免疫功能低下分型标准。方法采用聚合酶链反应(PCR)加HindⅢ酶切法测定红细胞CR1密度相关基因多态性,在32例SLE患者和48例正常人中用红细胞CR1花环(RBC-CR1R)及红细胞免疫复合物花环(RBC-ICR)测定红细胞CR1活性。结果16例活动期SLE患者中发现10例红细胞CR1密度相关基因组高表达型(HH型)占62.5%,而稳定期16例中有13例,占81.3%。这23例HH型SLE患者红细胞CR1活性(RBC-C3bR16.34±3.41,RBC-ICR10.17±3.02)比HL型(中表达型)、LL型(低表达型)高(8例HL型:RBC-C3bR13.50±4.50,RBC-ICR6.00±3.07和1例LL型:RBC-C3bR4.00,RBC-IC0.00),但与48例正常人明显不同(RBC-C3bR18.60±3.80,RBC-ICR4.50±1.50,P<0.01)。结论根据红细胞CR1基因型与CR1活性测定结果可将SLE患者红细胞CR1活性低下分为原发型、继发型和混合型,这种CR1免疫活性的差异可反映疾病的活动状况。
Objective To establish the standard of erythrocyte complement receptor type 1 (CR1) innate immunity in patients with systemic lupus erythematosus (SLE). Methods Polymerase chain reaction (PCR) and Hind Ⅲ restriction enzyme digestion were used to determine the polymorphism of erythrocyte CR1 density. In 32 SLE patients and 48 healthy controls, RBC-CR1R and erythrocyte immune complexes (RBC-ICR) assay CR1 activity of erythrocytes. Results Of 16 patients with active SLE, 10 cases of erythrocyte CR1 density-related genotypes (HH type) accounted for 62.5%, while in stable period of 16 cases, 13 cases (81.3%). The RBC-C3bR16.34 ± 3.41 and RBC-ICR10.17 ± 3.02 of 23 HH patients with SLE were higher than that of HL (middle expression) and LL (low expression) (8 HL: RBC-C3bR13.50 ± 4.50, RBC-ICR6.00 ± 3.07 and 1 case of LL type: RBC-C3bR4.00, RBC-IC0.00) but significantly different from that of 48 normal individuals (RBC-C3bR18.60 ± 3.80 , RBC-ICR4.50 ± 1.50, P <0.01). Conclusion According to the results of CR1 genotype and CR1 activity in erythrocytes, the CR1 activity of erythrocytes in patients with SLE can be divided into primary type, secondary type and mixed type. The differences in CR1 immunoreactivity reflect the disease activity.